Equity-Method Investment and Other Investments - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jul. 30, 2021
Schedule of Equity Method Investments [Line Items]
Equity method investment		$ 11,765	$ 32,455
Loss from equity method investments		(15,633)	(11,079)	$ (1,325)
AvenCell [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment		11,800	32,500
Investment Owned, Fair Value					$ 62,900
Loss from equity method investments		6,600	11,400	2,900
Investments in and Advances to Affiliates, at Fair Value, Gross Reductions		14,100	14,300	$ 1,800
Sparing Vision [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, Fair Value	$ 14,800	14,800	14,800
Sparing Vision [Member] | Series A2 Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Number of preferred stock received	83,316
Kyverna Therapeutics Inc [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, Fair Value		$ 10,000	$ 10,000
Kyverna Therapeutics Inc [Member] | Series B Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Number of preferred stock received		3,739,515
Fair value of stock received		$ 7,000
Number of stock additionally invested		1,602,649
Cash consideration received on sale of common stock		$ 3,000
Joint Venture AvenCell [Member] | AvenCell [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage		33.33%
Preferred Stock Purchase Agreement [Member] | Joint Venture AvenCell [Member] | AvenCell [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage					33.33%
Preferred Stock Purchase Agreement [Member] | Joint Venture AvenCell [Member] | Cellex and BXLS [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage					66.67%